EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Oxytetracycline-induced nephrotoxicosis in dogs after intravenous administration for experimental bone labeling


Laboratory Animal Science 46(5): 497-502
Oxytetracycline-induced nephrotoxicosis in dogs after intravenous administration for experimental bone labeling
Tetracyclines have been used as in vivo indicators of new bone formation because they form complexes with mineral at bone-forming surfaces. Four of 12 dogs in a bone-labeling study developed clinical signs of renal disease (vomiting, diarrhea, dehydration, and azotemia) within 1 to 2 days of receiving oxytetracycline at a bone-labeling dose of 25 mg/kg of body weight, once daily for 2 consecutive days. To delineate the relationship between oxytetracycline administration and renal damage, six dogs were given the bone-labeling dose intravenously and were subsequently evaluated by determination of clinical signs, serum biochemical analysis, urinalysis, and histologic examination (experiment 1). Drug administration was modified in the five dogs remaining in the bone-labeling orthopedic study. These dogs received the oxytetracycline dose as a slow intravenous infusion diluted with 250 nil of lactated Ringer's solution (experiment 2). All six dogs of experiment 1 developed persistent isosthenuria within 2 days of receiving the bone-labeling dose of oxytetracycline. Clinical illness (three of six dogs) was associated with azotemia, creatinemia, and hyperphosphatemia. AU dogs had multifocal, mild to moderate flattening of renal tubular epithelium, characteristic of nephrosis. None of the dogs of experiment 2 developed any clinical indications of renal disease, and the only biochemical abnormality was isosthenuria in two of the five dogs. Thus the development of clinical signs and biochemical abnormalities associated with the intravenous administration of oxytetracycline was obviated by the slow administration of a dilution of the calculated bone-labeling dose of the antibiotic.


Accession: 002914226

PMID: 8905581



Related references

Somatotropin thryotropin and acth induced changes in the cartilages and bones of the shoulder and knee joint in young dogs an experimental study using histological oxytetracycline bone labeling and micro radiographic methods. Journal of Small Animal Practice 12(11): 595-601, 1971

Oxytetracycline nephrotoxicosis in two dogs. Journal of the American Veterinary Medical Association 176(6): 530-531, 1980

Effect of intravenous calcium administration on gentamicin-induced nephrotoxicosis in ponies. American Journal of Veterinary Research 59(8): 1055-1062, 1998

Prevention of cisplatin-induced nephrotoxicosis in dogs, using hypertonic saline solution as the vehicle of administration. American Journal of Veterinary Research 54(12): 2175-2178, 1993

Experimental citrinin nephrotoxicosis in dogs: renal function evaluation. Veterinary and Human Toxicology 35(2): 136-140, 1993

Oxytetracycline-associated nephrotoxicosis in feedlot calves. Journal of the American Veterinary Medical Association 185(7): 793-795, 1984

Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms. Journal of the American Veterinary Medical Association 202(11): 1845-1848, 1993

Estimation of quantitative enzymuria in dogs with gentamicin-induced nephrotoxicosis using urine enzyme. Journal of veterinary internal medicine 9(5): 324-327, 1995

Effects of a prostaglandin E subscript 1 analogue, misoprostol, on gentamicin-induced nephrotoxicosis in dogs. 1996

Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989). Journal of the American Veterinary Medical Association 199(5): 613-616, 1991